Correlation between copy number variation genes (focal) and selected clinical features
Kidney Renal Clear Cell Carcinoma (Primary solid tumor)
22 February 2013  |  analyses__2013_02_22
Maintainer Information
Citation Information
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Correlation between copy number variation genes (focal) and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1RF5S7X
Overview
Introduction

This pipeline computes the correlation between significant copy number variation (cnv focal) genes and selected clinical features.

Summary

Testing the association between subtypes identified by 30 different clustering approaches and 8 clinical features across 493 patients, 26 significant findings detected with Q value < 0.25.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 1(1q24.1) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 2(1q32.1) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 3(3q26.32) mutation analysis'. These subtypes correlate to 'PATHOLOGY.T',  'PATHOLOGICSPREAD(M)', and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 4(4q32.1) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 5(5q35.1) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 6(7q36.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 7(8q24.22) mutation analysis'. These subtypes correlate to 'PATHOLOGY.T'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 8(10p14) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 9(17q24.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 10(Xp22.2) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 11(Xp11.4) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 12(Xq11.2) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 1(1p36.23) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 2(1p31.1) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 3(1q43) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 4(2q37.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 5(3p25.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 6(3p21.32) mutation analysis'. These subtypes correlate to 'PATHOLOGY.T' and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 7(3p12.2) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 8(3q11.2) mutation analysis'. These subtypes correlate to 'GENDER'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 9(4q34.3) mutation analysis'. These subtypes correlate to 'Time to Death',  'PATHOLOGY.T', and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 10(6q26) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 11(6q26) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 12(8p23.2) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 13(9p23) mutation analysis'. These subtypes correlate to 'Time to Death',  'PATHOLOGY.T',  'PATHOLOGICSPREAD(M)', and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 14(9p21.3) mutation analysis'. These subtypes correlate to 'Time to Death',  'PATHOLOGY.T',  'PATHOLOGICSPREAD(M)', and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 15(10q23.31) mutation analysis'. These subtypes correlate to 'PATHOLOGY.T'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 16(13q13.3) mutation analysis'. These subtypes correlate to 'Time to Death',  'PATHOLOGY.T', and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 17(14q31.1) mutation analysis'. These subtypes correlate to 'PATHOLOGY.T',  'PATHOLOGY.N',  'PATHOLOGICSPREAD(M)', and 'TUMOR.STAGE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 18(Xq23) mutation analysis'. These subtypes do not correlate to any clinical features.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between subtypes identified by 30 different clustering approaches and 8 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 26 significant findings detected.

Clinical
Features
Time
to
Death
AGE GENDER KARNOFSKY
PERFORMANCE
SCORE
PATHOLOGY
T
PATHOLOGY
N
PATHOLOGICSPREAD(M) TUMOR
STAGE
Statistical Tests logrank test t-test Fisher's exact test t-test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test
Amp Peak 1(1q24 1) 0.2
(1.00)
0.164
(1.00)
0.666
(1.00)
0.499
(1.00)
0.157
(1.00)
0.0751
(1.00)
0.339
(1.00)
0.298
(1.00)
Amp Peak 2(1q32 1) 0.437
(1.00)
0.0725
(1.00)
0.771
(1.00)
0.499
(1.00)
0.164
(1.00)
0.482
(1.00)
0.703
(1.00)
0.24
(1.00)
Amp Peak 3(3q26 32) 0.156
(1.00)
0.903
(1.00)
0.442
(1.00)
0.152
(1.00)
0.000107
(0.0238)
0.0593
(1.00)
7.09e-05
(0.0159)
2.55e-05
(0.00579)
Amp Peak 4(4q32 1) 0.0584
(1.00)
0.416
(1.00)
0.258
(1.00)
0.411
(1.00)
0.265
(1.00)
0.574
(1.00)
0.462
(1.00)
0.415
(1.00)
Amp Peak 5(5q35 1) 0.0454
(1.00)
0.0923
(1.00)
0.141
(1.00)
0.944
(1.00)
0.295
(1.00)
0.31
(1.00)
0.366
(1.00)
0.629
(1.00)
Amp Peak 6(7q36 3) 0.724
(1.00)
0.806
(1.00)
0.0352
(1.00)
0.57
(1.00)
0.0563
(1.00)
0.443
(1.00)
0.00523
(1.00)
0.0202
(1.00)
Amp Peak 7(8q24 22) 0.0527
(1.00)
0.0214
(1.00)
0.11
(1.00)
0.297
(1.00)
0.00112
(0.237)
0.74
(1.00)
0.053
(1.00)
0.00241
(0.5)
Amp Peak 8(10p14) 0.234
(1.00)
0.423
(1.00)
0.594
(1.00)
0.887
(1.00)
0.013
(1.00)
0.188
(1.00)
0.288
(1.00)
0.0494
(1.00)
Amp Peak 9(17q24 3) 0.0512
(1.00)
0.0662
(1.00)
0.858
(1.00)
0.471
(1.00)
0.482
(1.00)
0.359
(1.00)
0.244
(1.00)
0.857
(1.00)
Amp Peak 10(Xp22 2) 0.468
(1.00)
0.676
(1.00)
0.854
(1.00)
0.726
(1.00)
0.0837
(1.00)
0.668
(1.00)
0.0897
(1.00)
0.0108
(1.00)
Amp Peak 11(Xp11 4) 0.759
(1.00)
0.712
(1.00)
0.857
(1.00)
0.726
(1.00)
0.0695
(1.00)
0.668
(1.00)
0.0509
(1.00)
0.00533
(1.00)
Amp Peak 12(Xq11 2) 0.803
(1.00)
0.145
(1.00)
0.706
(1.00)
0.726
(1.00)
0.179
(1.00)
0.647
(1.00)
0.31
(1.00)
0.0584
(1.00)
Del Peak 1(1p36 23) 0.0495
(1.00)
0.123
(1.00)
0.123
(1.00)
0.284
(1.00)
0.111
(1.00)
1
(1.00)
0.0844
(1.00)
0.168
(1.00)
Del Peak 2(1p31 1) 0.219
(1.00)
0.0726
(1.00)
0.016
(1.00)
0.284
(1.00)
0.0536
(1.00)
0.722
(1.00)
0.294
(1.00)
0.181
(1.00)
Del Peak 3(1q43) 0.704
(1.00)
0.335
(1.00)
1
(1.00)
0.0712
(1.00)
0.374
(1.00)
1
(1.00)
0.749
(1.00)
Del Peak 4(2q37 3) 0.673
(1.00)
0.63
(1.00)
0.153
(1.00)
0.822
(1.00)
1
(1.00)
0.402
(1.00)
0.556
(1.00)
Del Peak 5(3p25 3) 0.783
(1.00)
0.788
(1.00)
0.569
(1.00)
0.0817
(1.00)
0.00144
(0.303)
1
(1.00)
0.707
(1.00)
0.0129
(1.00)
Del Peak 6(3p21 32) 0.498
(1.00)
0.704
(1.00)
0.772
(1.00)
0.0817
(1.00)
3.34e-05
(0.00756)
1
(1.00)
0.333
(1.00)
0.00053
(0.115)
Del Peak 7(3p12 2) 0.614
(1.00)
0.761
(1.00)
0.00221
(0.461)
0.741
(1.00)
0.217
(1.00)
0.626
(1.00)
0.53
(1.00)
0.231
(1.00)
Del Peak 8(3q11 2) 0.635
(1.00)
0.0111
(1.00)
1.32e-07
(3.1e-05)
0.749
(1.00)
0.134
(1.00)
0.787
(1.00)
0.591
(1.00)
0.45
(1.00)
Del Peak 9(4q34 3) 0.000557
(0.12)
0.568
(1.00)
0.433
(1.00)
0.0261
(1.00)
4.27e-07
(9.98e-05)
1
(1.00)
0.00862
(1.00)
2.7e-06
(0.000626)
Del Peak 10(6q26) 0.565
(1.00)
0.287
(1.00)
0.012
(1.00)
0.256
(1.00)
0.621
(1.00)
0.0195
(1.00)
0.41
(1.00)
0.32
(1.00)
Del Peak 11(6q26) 0.589
(1.00)
0.226
(1.00)
0.00648
(1.00)
0.256
(1.00)
0.621
(1.00)
0.0195
(1.00)
0.41
(1.00)
0.32
(1.00)
Del Peak 12(8p23 2) 0.0385
(1.00)
0.139
(1.00)
0.256
(1.00)
0.893
(1.00)
0.176
(1.00)
0.786
(1.00)
0.055
(1.00)
0.14
(1.00)
Del Peak 13(9p23) 0.000138
(0.0304)
0.0136
(1.00)
0.00361
(0.744)
0.656
(1.00)
1.39e-05
(0.0032)
0.262
(1.00)
0.000876
(0.187)
5.62e-06
(0.0013)
Del Peak 14(9p21 3) 2.03e-06
(0.000473)
0.0261
(1.00)
0.00144
(0.303)
0.656
(1.00)
1.01e-07
(2.4e-05)
0.0589
(1.00)
6.93e-05
(0.0156)
3.39e-08
(8.03e-06)
Del Peak 15(10q23 31) 0.217
(1.00)
0.209
(1.00)
0.0272
(1.00)
0.764
(1.00)
0.000477
(0.104)
1
(1.00)
0.333
(1.00)
0.0177
(1.00)
Del Peak 16(13q13 3) 0.000848
(0.182)
0.884
(1.00)
0.794
(1.00)
0.748
(1.00)
1.48e-05
(0.0034)
0.325
(1.00)
0.0377
(1.00)
0.000348
(0.0762)
Del Peak 17(14q31 1) 0.00179
(0.374)
0.055
(1.00)
0.393
(1.00)
0.0872
(1.00)
0.000107
(0.0238)
0.000113
(0.0249)
0.00101
(0.216)
2.42e-05
(0.00553)
Del Peak 18(Xq23) 0.287
(1.00)
0.669
(1.00)
0.234
(1.00)
0.297
(1.00)
0.657
(1.00)
0.168
(1.00)
0.142
(1.00)
Clustering Approach #1: 'Amp Peak 1(1q24.1) mutation analysis'

Table S1.  Description of clustering approach #1: 'Amp Peak 1(1q24.1) mutation analysis'

Cluster Labels AMP PEAK 1(1Q24.1) MUTATED AMP PEAK 1(1Q24.1) WILD-TYPE
Number of samples 60 433
Clustering Approach #2: 'Amp Peak 2(1q32.1) mutation analysis'

Table S2.  Description of clustering approach #2: 'Amp Peak 2(1q32.1) mutation analysis'

Cluster Labels AMP PEAK 2(1Q32.1) MUTATED AMP PEAK 2(1Q32.1) WILD-TYPE
Number of samples 59 434
Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis'

Table S3.  Description of clustering approach #3: 'Amp Peak 3(3q26.32) mutation analysis'

Cluster Labels AMP PEAK 3(3Q26.32) MUTATED AMP PEAK 3(3Q26.32) WILD-TYPE
Number of samples 80 413
'Amp Peak 3(3q26.32) mutation analysis' versus 'PATHOLOGY.T'

P value = 0.000107 (Fisher's exact test), Q value = 0.024

Table S4.  Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
AMP PEAK 3(3Q26.32) MUTATED 24 8 44 4
AMP PEAK 3(3Q26.32) WILD-TYPE 218 56 132 7

Figure S1.  Get High-res Image Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Amp Peak 3(3q26.32) mutation analysis' versus 'PATHOLOGICSPREAD(M)'

P value = 7.09e-05 (Fisher's exact test), Q value = 0.016

Table S5.  Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

nPatients M0 M1
ALL 417 76
AMP PEAK 3(3Q26.32) MUTATED 55 25
AMP PEAK 3(3Q26.32) WILD-TYPE 362 51

Figure S2.  Get High-res Image Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

'Amp Peak 3(3q26.32) mutation analysis' versus 'TUMOR.STAGE'

P value = 2.55e-05 (Fisher's exact test), Q value = 0.0058

Table S6.  Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
AMP PEAK 3(3Q26.32) MUTATED 23 6 25 26
AMP PEAK 3(3Q26.32) WILD-TYPE 215 46 98 54

Figure S3.  Get High-res Image Clustering Approach #3: 'Amp Peak 3(3q26.32) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #4: 'Amp Peak 4(4q32.1) mutation analysis'

Table S7.  Description of clustering approach #4: 'Amp Peak 4(4q32.1) mutation analysis'

Cluster Labels AMP PEAK 4(4Q32.1) MUTATED AMP PEAK 4(4Q32.1) WILD-TYPE
Number of samples 14 479
Clustering Approach #5: 'Amp Peak 5(5q35.1) mutation analysis'

Table S8.  Description of clustering approach #5: 'Amp Peak 5(5q35.1) mutation analysis'

Cluster Labels AMP PEAK 5(5Q35.1) MUTATED AMP PEAK 5(5Q35.1) WILD-TYPE
Number of samples 311 182
Clustering Approach #6: 'Amp Peak 6(7q36.3) mutation analysis'

Table S9.  Description of clustering approach #6: 'Amp Peak 6(7q36.3) mutation analysis'

Cluster Labels AMP PEAK 6(7Q36.3) MUTATED AMP PEAK 6(7Q36.3) WILD-TYPE
Number of samples 163 330
Clustering Approach #7: 'Amp Peak 7(8q24.22) mutation analysis'

Table S10.  Description of clustering approach #7: 'Amp Peak 7(8q24.22) mutation analysis'

Cluster Labels AMP PEAK 7(8Q24.22) MUTATED AMP PEAK 7(8Q24.22) WILD-TYPE
Number of samples 73 420
'Amp Peak 7(8q24.22) mutation analysis' versus 'PATHOLOGY.T'

P value = 0.00112 (Fisher's exact test), Q value = 0.24

Table S11.  Clustering Approach #7: 'Amp Peak 7(8q24.22) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
AMP PEAK 7(8Q24.22) MUTATED 21 11 39 2
AMP PEAK 7(8Q24.22) WILD-TYPE 221 53 137 9

Figure S4.  Get High-res Image Clustering Approach #7: 'Amp Peak 7(8q24.22) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

Clustering Approach #8: 'Amp Peak 8(10p14) mutation analysis'

Table S12.  Description of clustering approach #8: 'Amp Peak 8(10p14) mutation analysis'

Cluster Labels AMP PEAK 8(10P14) MUTATED AMP PEAK 8(10P14) WILD-TYPE
Number of samples 16 477
Clustering Approach #9: 'Amp Peak 9(17q24.3) mutation analysis'

Table S13.  Description of clustering approach #9: 'Amp Peak 9(17q24.3) mutation analysis'

Cluster Labels AMP PEAK 9(17Q24.3) MUTATED AMP PEAK 9(17Q24.3) WILD-TYPE
Number of samples 37 456
Clustering Approach #10: 'Amp Peak 10(Xp22.2) mutation analysis'

Table S14.  Description of clustering approach #10: 'Amp Peak 10(Xp22.2) mutation analysis'

Cluster Labels AMP PEAK 10(XP22.2) MUTATED AMP PEAK 10(XP22.2) WILD-TYPE
Number of samples 35 458
Clustering Approach #11: 'Amp Peak 11(Xp11.4) mutation analysis'

Table S15.  Description of clustering approach #11: 'Amp Peak 11(Xp11.4) mutation analysis'

Cluster Labels AMP PEAK 11(XP11.4) MUTATED AMP PEAK 11(XP11.4) WILD-TYPE
Number of samples 36 457
Clustering Approach #12: 'Amp Peak 12(Xq11.2) mutation analysis'

Table S16.  Description of clustering approach #12: 'Amp Peak 12(Xq11.2) mutation analysis'

Cluster Labels AMP PEAK 12(XQ11.2) MUTATED AMP PEAK 12(XQ11.2) WILD-TYPE
Number of samples 32 461
Clustering Approach #13: 'Del Peak 1(1p36.23) mutation analysis'

Table S17.  Description of clustering approach #13: 'Del Peak 1(1p36.23) mutation analysis'

Cluster Labels DEL PEAK 1(1P36.23) MUTATED DEL PEAK 1(1P36.23) WILD-TYPE
Number of samples 98 395
Clustering Approach #14: 'Del Peak 2(1p31.1) mutation analysis'

Table S18.  Description of clustering approach #14: 'Del Peak 2(1p31.1) mutation analysis'

Cluster Labels DEL PEAK 2(1P31.1) MUTATED DEL PEAK 2(1P31.1) WILD-TYPE
Number of samples 72 421
Clustering Approach #15: 'Del Peak 3(1q43) mutation analysis'

Table S19.  Description of clustering approach #15: 'Del Peak 3(1q43) mutation analysis'

Cluster Labels DEL PEAK 3(1Q43) MUTATED DEL PEAK 3(1Q43) WILD-TYPE
Number of samples 38 455
Clustering Approach #16: 'Del Peak 4(2q37.3) mutation analysis'

Table S20.  Description of clustering approach #16: 'Del Peak 4(2q37.3) mutation analysis'

Cluster Labels DEL PEAK 4(2Q37.3) MUTATED DEL PEAK 4(2Q37.3) WILD-TYPE
Number of samples 48 445
Clustering Approach #17: 'Del Peak 5(3p25.3) mutation analysis'

Table S21.  Description of clustering approach #17: 'Del Peak 5(3p25.3) mutation analysis'

Cluster Labels DEL PEAK 5(3P25.3) MUTATED DEL PEAK 5(3P25.3) WILD-TYPE
Number of samples 432 61
Clustering Approach #18: 'Del Peak 6(3p21.32) mutation analysis'

Table S22.  Description of clustering approach #18: 'Del Peak 6(3p21.32) mutation analysis'

Cluster Labels DEL PEAK 6(3P21.32) MUTATED DEL PEAK 6(3P21.32) WILD-TYPE
Number of samples 435 58
'Del Peak 6(3p21.32) mutation analysis' versus 'PATHOLOGY.T'

P value = 3.34e-05 (Fisher's exact test), Q value = 0.0076

Table S23.  Clustering Approach #18: 'Del Peak 6(3p21.32) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 6(3P21.32) MUTATED 209 52 168 6
DEL PEAK 6(3P21.32) WILD-TYPE 33 12 8 5

Figure S5.  Get High-res Image Clustering Approach #18: 'Del Peak 6(3p21.32) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Del Peak 6(3p21.32) mutation analysis' versus 'TUMOR.STAGE'

P value = 0.00053 (Fisher's exact test), Q value = 0.12

Table S24.  Clustering Approach #18: 'Del Peak 6(3p21.32) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
DEL PEAK 6(3P21.32) MUTATED 205 40 119 71
DEL PEAK 6(3P21.32) WILD-TYPE 33 12 4 9

Figure S6.  Get High-res Image Clustering Approach #18: 'Del Peak 6(3p21.32) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #19: 'Del Peak 7(3p12.2) mutation analysis'

Table S25.  Description of clustering approach #19: 'Del Peak 7(3p12.2) mutation analysis'

Cluster Labels DEL PEAK 7(3P12.2) MUTATED DEL PEAK 7(3P12.2) WILD-TYPE
Number of samples 283 210
Clustering Approach #20: 'Del Peak 8(3q11.2) mutation analysis'

Table S26.  Description of clustering approach #20: 'Del Peak 8(3q11.2) mutation analysis'

Cluster Labels DEL PEAK 8(3Q11.2) MUTATED DEL PEAK 8(3Q11.2) WILD-TYPE
Number of samples 150 343
'Del Peak 8(3q11.2) mutation analysis' versus 'GENDER'

P value = 1.32e-07 (Fisher's exact test), Q value = 3.1e-05

Table S27.  Clustering Approach #20: 'Del Peak 8(3q11.2) mutation analysis' versus Clinical Feature #3: 'GENDER'

nPatients FEMALE MALE
ALL 171 322
DEL PEAK 8(3Q11.2) MUTATED 27 123
DEL PEAK 8(3Q11.2) WILD-TYPE 144 199

Figure S7.  Get High-res Image Clustering Approach #20: 'Del Peak 8(3q11.2) mutation analysis' versus Clinical Feature #3: 'GENDER'

Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis'

Table S28.  Description of clustering approach #21: 'Del Peak 9(4q34.3) mutation analysis'

Cluster Labels DEL PEAK 9(4Q34.3) MUTATED DEL PEAK 9(4Q34.3) WILD-TYPE
Number of samples 76 417
'Del Peak 9(4q34.3) mutation analysis' versus 'Time to Death'

P value = 0.000557 (logrank test), Q value = 0.12

Table S29.  Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 490 158 0.1 - 111.0 (35.2)
DEL PEAK 9(4Q34.3) MUTATED 76 38 0.2 - 91.4 (35.1)
DEL PEAK 9(4Q34.3) WILD-TYPE 414 120 0.1 - 111.0 (35.2)

Figure S8.  Get High-res Image Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis' versus Clinical Feature #1: 'Time to Death'

'Del Peak 9(4q34.3) mutation analysis' versus 'PATHOLOGY.T'

P value = 4.27e-07 (Fisher's exact test), Q value = 1e-04

Table S30.  Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 9(4Q34.3) MUTATED 19 8 43 6
DEL PEAK 9(4Q34.3) WILD-TYPE 223 56 133 5

Figure S9.  Get High-res Image Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Del Peak 9(4q34.3) mutation analysis' versus 'TUMOR.STAGE'

P value = 2.7e-06 (Fisher's exact test), Q value = 0.00063

Table S31.  Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
DEL PEAK 9(4Q34.3) MUTATED 18 6 30 22
DEL PEAK 9(4Q34.3) WILD-TYPE 220 46 93 58

Figure S10.  Get High-res Image Clustering Approach #21: 'Del Peak 9(4q34.3) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #22: 'Del Peak 10(6q26) mutation analysis'

Table S32.  Description of clustering approach #22: 'Del Peak 10(6q26) mutation analysis'

Cluster Labels DEL PEAK 10(6Q26) MUTATED DEL PEAK 10(6Q26) WILD-TYPE
Number of samples 142 351
Clustering Approach #23: 'Del Peak 11(6q26) mutation analysis'

Table S33.  Description of clustering approach #23: 'Del Peak 11(6q26) mutation analysis'

Cluster Labels DEL PEAK 11(6Q26) MUTATED DEL PEAK 11(6Q26) WILD-TYPE
Number of samples 142 351
Clustering Approach #24: 'Del Peak 12(8p23.2) mutation analysis'

Table S34.  Description of clustering approach #24: 'Del Peak 12(8p23.2) mutation analysis'

Cluster Labels DEL PEAK 12(8P23.2) MUTATED DEL PEAK 12(8P23.2) WILD-TYPE
Number of samples 146 347
Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis'

Table S35.  Description of clustering approach #25: 'Del Peak 13(9p23) mutation analysis'

Cluster Labels DEL PEAK 13(9P23) MUTATED DEL PEAK 13(9P23) WILD-TYPE
Number of samples 144 349
'Del Peak 13(9p23) mutation analysis' versus 'Time to Death'

P value = 0.000138 (logrank test), Q value = 0.03

Table S36.  Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 490 158 0.1 - 111.0 (35.2)
DEL PEAK 13(9P23) MUTATED 143 65 0.2 - 109.9 (36.1)
DEL PEAK 13(9P23) WILD-TYPE 347 93 0.1 - 111.0 (34.6)

Figure S11.  Get High-res Image Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #1: 'Time to Death'

'Del Peak 13(9p23) mutation analysis' versus 'PATHOLOGY.T'

P value = 1.39e-05 (Fisher's exact test), Q value = 0.0032

Table S37.  Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 13(9P23) MUTATED 50 15 74 5
DEL PEAK 13(9P23) WILD-TYPE 192 49 102 6

Figure S12.  Get High-res Image Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Del Peak 13(9p23) mutation analysis' versus 'PATHOLOGICSPREAD(M)'

P value = 0.000876 (Fisher's exact test), Q value = 0.19

Table S38.  Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

nPatients M0 M1
ALL 417 76
DEL PEAK 13(9P23) MUTATED 109 35
DEL PEAK 13(9P23) WILD-TYPE 308 41

Figure S13.  Get High-res Image Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

'Del Peak 13(9p23) mutation analysis' versus 'TUMOR.STAGE'

P value = 5.62e-06 (Fisher's exact test), Q value = 0.0013

Table S39.  Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
DEL PEAK 13(9P23) MUTATED 48 11 49 36
DEL PEAK 13(9P23) WILD-TYPE 190 41 74 44

Figure S14.  Get High-res Image Clustering Approach #25: 'Del Peak 13(9p23) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis'

Table S40.  Description of clustering approach #26: 'Del Peak 14(9p21.3) mutation analysis'

Cluster Labels DEL PEAK 14(9P21.3) MUTATED DEL PEAK 14(9P21.3) WILD-TYPE
Number of samples 152 341
'Del Peak 14(9p21.3) mutation analysis' versus 'Time to Death'

P value = 2.03e-06 (logrank test), Q value = 0.00047

Table S41.  Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 490 158 0.1 - 111.0 (35.2)
DEL PEAK 14(9P21.3) MUTATED 152 72 0.2 - 109.9 (31.5)
DEL PEAK 14(9P21.3) WILD-TYPE 338 86 0.1 - 111.0 (36.2)

Figure S15.  Get High-res Image Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #1: 'Time to Death'

'Del Peak 14(9p21.3) mutation analysis' versus 'PATHOLOGY.T'

P value = 1.01e-07 (Fisher's exact test), Q value = 2.4e-05

Table S42.  Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 14(9P21.3) MUTATED 51 14 81 6
DEL PEAK 14(9P21.3) WILD-TYPE 191 50 95 5

Figure S16.  Get High-res Image Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Del Peak 14(9p21.3) mutation analysis' versus 'PATHOLOGICSPREAD(M)'

P value = 6.93e-05 (Fisher's exact test), Q value = 0.016

Table S43.  Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

nPatients M0 M1
ALL 417 76
DEL PEAK 14(9P21.3) MUTATED 113 39
DEL PEAK 14(9P21.3) WILD-TYPE 304 37

Figure S17.  Get High-res Image Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

'Del Peak 14(9p21.3) mutation analysis' versus 'TUMOR.STAGE'

P value = 3.39e-08 (Fisher's exact test), Q value = 8e-06

Table S44.  Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
DEL PEAK 14(9P21.3) MUTATED 49 10 52 41
DEL PEAK 14(9P21.3) WILD-TYPE 189 42 71 39

Figure S18.  Get High-res Image Clustering Approach #26: 'Del Peak 14(9p21.3) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #27: 'Del Peak 15(10q23.31) mutation analysis'

Table S45.  Description of clustering approach #27: 'Del Peak 15(10q23.31) mutation analysis'

Cluster Labels DEL PEAK 15(10Q23.31) MUTATED DEL PEAK 15(10Q23.31) WILD-TYPE
Number of samples 90 403
'Del Peak 15(10q23.31) mutation analysis' versus 'PATHOLOGY.T'

P value = 0.000477 (Fisher's exact test), Q value = 0.1

Table S46.  Clustering Approach #27: 'Del Peak 15(10q23.31) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 15(10Q23.31) MUTATED 31 10 43 6
DEL PEAK 15(10Q23.31) WILD-TYPE 211 54 133 5

Figure S19.  Get High-res Image Clustering Approach #27: 'Del Peak 15(10q23.31) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis'

Table S47.  Description of clustering approach #28: 'Del Peak 16(13q13.3) mutation analysis'

Cluster Labels DEL PEAK 16(13Q13.3) MUTATED DEL PEAK 16(13Q13.3) WILD-TYPE
Number of samples 76 417
'Del Peak 16(13q13.3) mutation analysis' versus 'Time to Death'

P value = 0.000848 (logrank test), Q value = 0.18

Table S48.  Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 490 158 0.1 - 111.0 (35.2)
DEL PEAK 16(13Q13.3) MUTATED 75 34 0.1 - 89.4 (28.5)
DEL PEAK 16(13Q13.3) WILD-TYPE 415 124 0.1 - 111.0 (36.3)

Figure S20.  Get High-res Image Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis' versus Clinical Feature #1: 'Time to Death'

'Del Peak 16(13q13.3) mutation analysis' versus 'PATHOLOGY.T'

P value = 1.48e-05 (Fisher's exact test), Q value = 0.0034

Table S49.  Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 16(13Q13.3) MUTATED 28 3 39 6
DEL PEAK 16(13Q13.3) WILD-TYPE 214 61 137 5

Figure S21.  Get High-res Image Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Del Peak 16(13q13.3) mutation analysis' versus 'TUMOR.STAGE'

P value = 0.000348 (Fisher's exact test), Q value = 0.076

Table S50.  Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
DEL PEAK 16(13Q13.3) MUTATED 27 2 27 20
DEL PEAK 16(13Q13.3) WILD-TYPE 211 50 96 60

Figure S22.  Get High-res Image Clustering Approach #28: 'Del Peak 16(13q13.3) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis'

Table S51.  Description of clustering approach #29: 'Del Peak 17(14q31.1) mutation analysis'

Cluster Labels DEL PEAK 17(14Q31.1) MUTATED DEL PEAK 17(14Q31.1) WILD-TYPE
Number of samples 218 275
'Del Peak 17(14q31.1) mutation analysis' versus 'PATHOLOGY.T'

P value = 0.000107 (Fisher's exact test), Q value = 0.024

Table S52.  Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

nPatients T1 T2 T3 T4
ALL 242 64 176 11
DEL PEAK 17(14Q31.1) MUTATED 83 35 96 4
DEL PEAK 17(14Q31.1) WILD-TYPE 159 29 80 7

Figure S23.  Get High-res Image Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #5: 'PATHOLOGY.T'

'Del Peak 17(14q31.1) mutation analysis' versus 'PATHOLOGY.N'

P value = 0.000113 (Fisher's exact test), Q value = 0.025

Table S53.  Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #6: 'PATHOLOGY.N'

nPatients 0 1
ALL 228 18
DEL PEAK 17(14Q31.1) MUTATED 96 16
DEL PEAK 17(14Q31.1) WILD-TYPE 132 2

Figure S24.  Get High-res Image Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #6: 'PATHOLOGY.N'

'Del Peak 17(14q31.1) mutation analysis' versus 'PATHOLOGICSPREAD(M)'

P value = 0.00101 (Fisher's exact test), Q value = 0.22

Table S54.  Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

nPatients M0 M1
ALL 417 76
DEL PEAK 17(14Q31.1) MUTATED 171 47
DEL PEAK 17(14Q31.1) WILD-TYPE 246 29

Figure S25.  Get High-res Image Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #7: 'PATHOLOGICSPREAD(M)'

'Del Peak 17(14q31.1) mutation analysis' versus 'TUMOR.STAGE'

P value = 2.42e-05 (Fisher's exact test), Q value = 0.0055

Table S55.  Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 238 52 123 80
DEL PEAK 17(14Q31.1) MUTATED 79 25 68 46
DEL PEAK 17(14Q31.1) WILD-TYPE 159 27 55 34

Figure S26.  Get High-res Image Clustering Approach #29: 'Del Peak 17(14q31.1) mutation analysis' versus Clinical Feature #8: 'TUMOR.STAGE'

Clustering Approach #30: 'Del Peak 18(Xq23) mutation analysis'

Table S56.  Description of clustering approach #30: 'Del Peak 18(Xq23) mutation analysis'

Cluster Labels DEL PEAK 18(XQ23) MUTATED DEL PEAK 18(XQ23) WILD-TYPE
Number of samples 55 438
Methods & Data
Input
  • Cluster data file = all_lesions.conf_99.cnv.cluster.txt

  • Clinical data file = KIRC-TP.clin.merged.picked.txt

  • Number of patients = 493

  • Number of clustering approaches = 30

  • Number of selected clinical features = 8

  • Exclude small clusters that include fewer than K patients, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between two tumor subtypes using 't.test' function in R

Fisher's exact test

For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)